The relevance of pharmacogenetics to schizophrenia

Current Opinion in Psychiatry

Volumn 16, Issue 2, 2003, Pages 171-174

  Malhotra, Anil K ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotic; Gene; Pharmacogenetics; Polymorphism; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR;

DRUG EFFICACY; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PREDICTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0037335215     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200303000-00005     Document Type: Review

References (26)

1. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11:2517-2530.
2. Kane J, Honigferd G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796.
3. Malhotra AK, Goldman D. Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry 1999; 45:544-550.
4. 2A receptor gene. Lancet 1995; 346:281-282.
5. 2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1998; 153:1092-1094.
6. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32:93-99.
7. 2A receptor gene. Am J Psychiatry 2002; 159:1593-1595. This is the first published study to examine the relationship between risperidone and serotonin receptor genetic variation.
8. Kaiser R, Tremblay PB, Schmider J, et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 2001; 6:179-185.
9. 6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001; 47:49-58.
10. 2 receptor gene and dozapine response. Schizophr Res 1999; 36:92-93.
11. Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000; 10:335-341.
12. Arranz MJ, Li T, Munro J, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 1998; 8:481-484.
13. Shafer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am J Psychiatry 2001; 158:802-804. This is a well-designed study that finds a relatively strong relationship between dopamine D2 receptor genotype and response to haloperidol.
14. Mata I, Arranz MJ, Lai T, et al. The serotonergic system influences individual's response to risperidone [abstract]. Am J Med Genetics 2002; 114:728.
15. Suzuki A, Kondo T, Mihara K, et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11:545-550.
16. Athanasiou MC, Malhotra AK, Xu C, Stephens JC. Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet 2002; 12:89-96. This paper reviews the use of haplotypes in psychiatric pharmacogenetic studies and the potential commercial applications of this strategy.
17. Ozdemir V, Basile VS, Masellis M, Kennedy JL. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. J Biochem Biophys Methods 2001; 47:151-157.
18. Garcia-Barcelo MM, Lam LCW, Ungvari GS, et al. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001; 108:671-677.
19. Schulze TG, Schumacher J, Muller DJ, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A12) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105:498-501.
20. Hori H, Ohmori O, Shinkai T, et al. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105:774-778.
21. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly poiymorphism. Neuropsychopharmacology 2002; 27:105-119. This comprehensive analysis was conducted by pooling data from several centers around the world and suggests that dopamine D3 receptor genotypes play a role in susceptibility to tardive dyskinesia. These data suggest that multicenter collaborations may be critical for the detection of the genetic factors that underlie many complex pharmacogenetic traits.
22. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6:225-229.
23. 2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001; 158:1714-1716.
24. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
25. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359:2086-2087. This is the first study to utilize drug-naïve, first-episode schizophrenia patients, and includes potentially important data suggesting a genetic susceptibility to antipsychotic drug-induced weight gain.
26. Malhotra AK. Pharmacogenomics and schizophrenia: clinical implications. Pharmacogenomics J 2001; 1:109-114.